Terms: = Skin cancer AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790 AND Treatment
15 results:
1. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
2. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract] [Full Text] [Related]
3. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
[TBL] [Abstract] [Full Text] [Related]
4. Aberrant epigenetic regulation of RARβ by tet2 is involved in cutaneous squamous cell carcinoma resistance to retinoic acid.
Zhang X; Cong Y; Chu Z; Shi L; Zheng Y; Zhao Q; Geng S; Guo K
Int J Biochem Cell Biol; 2022 Apr; 145():106190. PubMed ID: 35248720
[TBL] [Abstract] [Full Text] [Related]
5. Complete Bone Marrow Necrosis with Charcot-Leyden Crystals Caused by Myeloid Neoplasm with Mutated NPM1 and tet2.
Saito K; Sato T; Notohara K; Nannya Y; Ogawa S; Ueda Y
Intern Med; 2022 Nov; 61(21):3265-3269. PubMed ID: 35185048
[TBL] [Abstract] [Full Text] [Related]
6. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract] [Full Text] [Related]
7. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract] [Full Text] [Related]
8. tet2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract] [Full Text] [Related]
9. [Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine].
Sukegawa S; Sakata-Yanagimoto M; Matsuoka R; Momose H; Kiyoki Y; Noguchi M; Nakamura N; Watanabe R; Fujimoto M; Yokoyama Y; Nishikii H; Kato T; Kusakabe M; Kurita N; Obara N; Hasegawa Y; Chiba S
Rinsho Ketsueki; 2018; 59(12):2567-2573. PubMed ID: 30626790
[TBL] [Abstract] [Full Text] [Related]
10. [New molecular pathological strategies for malignant iris tumors].
Kakkassery V; Jünemann AM; Scheef BO; Grisanti S; Heindl LM
Ophthalmologe; 2019 Apr; 116(4):324-331. PubMed ID: 30623224
[TBL] [Abstract] [Full Text] [Related]
11. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.
Sapienza MR; Abate F; Melle F; Orecchioni S; Fuligni F; Etebari M; Tabanelli V; Laginestra MA; Pileri A; Motta G; Rossi M; Agostinelli C; Sabattini E; Pimpinelli N; Truni M; Falini B; Cerroni L; Talarico G; Piccioni R; Amente S; Indio V; Tarantino G; Brundu F; Paulli M; Berti E; Facchetti F; Dellino GI; Bertolini F; Tripodo C; Rabadan R; Pileri SA
Haematologica; 2019 Apr; 104(4):729-737. PubMed ID: 30381297
[TBL] [Abstract] [Full Text] [Related]
12. Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery.
Gambichler T; Rüddel I; Hessam S; Bechara FG; Stockfleth E; Schmitz L
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1485-1491. PubMed ID: 29478287
[TBL] [Abstract] [Full Text] [Related]
13. The DNA Methylcytosine Dioxygenase tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression.
Pan W; Zhu S; Qu K; Meeth K; Cheng J; He K; Ma H; Liao Y; Wen X; Roden C; Tobiasova Z; Wei Z; Zhao J; Liu J; Zheng J; Guo B; Khan SA; Bosenberg M; Flavell RA; Lu J
Immunity; 2017 Aug; 47(2):284-297.e5. PubMed ID: 28813659
[TBL] [Abstract] [Full Text] [Related]
14. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
[TBL] [Abstract] [Full Text] [Related]
15. Loss of function of tet2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
De Vita S; Schneider RK; Garcia M; Wood J; Gavillet M; Ebert BL; Gerbaulet A; Roers A; Levine RL; Mullally A; Williams DA
PLoS One; 2014; 9(5):e96209. PubMed ID: 24788138
[TBL] [Abstract] [Full Text] [Related]
